Publication | Closed Access

The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia

Hematological MalignancyChronic Myeloid LeukemiaMedicineMixed-phenotype Acute LeukemiaHematologyMyeloid NeoplasiaPharmacotherapySecond-line TherapyOncologyRadiation OncologyGeneric ImatinibHealth Sciences